GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Selling and Marketing Expense

Sage Therapeutics (STU:SG7) Selling and Marketing Expense : €0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Sage Therapeutics's Selling and Marketing Expense for the three months ended in Mar. 2025 was €0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Sage Therapeutics Selling and Marketing Expense Historical Data

The historical data trend for Sage Therapeutics's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Selling and Marketing Expense Chart

Sage Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sage Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sage Therapeutics Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sage Therapeutics Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Selling and Marketing Expense
Comparable Companies
AMLX CGEM MNMD TBPH RGNX DNA URGN UPB VERV NWBO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
SAGE:USA SG7:Germany
Address
55 Cambridge Parkway, Cambridge, MA, USA, 02142
Website
https://www.sagerx.com
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Headlines

No Headlines